Biosimilar Market Will Reach $3.7 Billion in 2015
LONDON, March 28, 2011-The global biosimilars market will grow from $243m in 2010 to $3.7bn in 2015 according to latest research from independent analyst, Datamonitor*.
More than 30 branded biologics with sales of $51bn set to lose patent exclusivity between 2011 and 2015*, and uptake of biosimilar versions will drive market growth.
Mark Hollis, healthcare analyst at Datamonitor, comments: “With the market shares of first-generation biologic drugs stagnating or declining, biosimilar monoclonal antibodies (MAbs) and second-generation biosimilars represent a high-value proposition for biosimilar manufacturers and key drivers for future growth”.
“However, despite the introduction of biosimilar approval pathways in the US, EU and Japan, the growing use of biologics and the need for more cost-effective treatments, there remain a large number of barriers to achieving commercial success in developed markets.”
Nevertheless, although existing biosimilar players have the advantage of an established reputation and relationships with key stakeholders, branded pharma companies are increasingly looking to biosimilars as one route to drive sales going forward, using partnership and M&A deals to achieve their goals.
Consequently, Datamonitor argues that the future biosimilars market in the US, EU and Japan will continue to remain dominated by the existing biosimilars players, with the addition of select branded pharma companies. Furthermore, emerging market biosimilar players are now looking to expand into global markets too, through partnerships with international pharma companies.
Pharmaceutical Key Trends 2011 – Biosimilar Market Overview & Generics Market Outlook: 2015
Mark Hollis is available for comment.
More information is available from the Datamonitor Group Media Team. Please contact Joe Dixon on +44 161 238 4083 or firstname.lastname@example.org.
For US, please contact Alan Sott on +1 570 687 9315.
For Asia-Pacific, please contact Denis Mason on +61 2 8705 6903.
Datamonitor is a leading provider of online database and analysis services for key industry sectors. We help our clients, 5000 of the world's leading companies, to address complex strategic issues. Through our proprietary databases and wealth of expertise, we provide clients with unbiased expert analysis and in-depth forecasts for seven industry sectors: Automotive, Consumer Packaged Goods, Energy, Financial Services, Pharmaceuticals and Healthcare, Technology, Transport and Logistics.
Posted: March 2011